Vanik™ — A New Standard in Targeted Therapy
Vandoz Pharma is proud to introduce Vanik (vanelizumab-vxk), a first-in-class monoclonal antibody indicated for the treatment of moderate-to-severe relapsing eosinophilic granulomatosis with polyangiitis (EGPA) in adults whose disease is inadequately controlled with standard immunosuppressive therapy. Vanik delivers precision-targeted IL-5 receptor antagonism, addressing the underlying driver of disease with a profile designed for real-world patients.
This portal provides healthcare professionals and patients with comprehensive prescribing information, safety data, support program resources, and clinical tools to support informed treatment decisions.
HCP Portal Access

⚠ Important Safety Information: Vanik carries a BOXED WARNING for serious hypersensitivity reactions including anaphylaxis. Please review the full Prescribing Information before initiating therapy. See ISI summary below.
Drug Overview & Clinical Profile
Vanik is engineered for precision. Below is a summary of its mechanism, available formulations, administration guidance, and storage requirements for clinical and pharmacy reference.
Mechanism of Action
Vanik is a humanized IgG4 monoclonal antibody that selectively binds to the IL-5 receptor alpha subunit on eosinophils and basophils, inhibiting IL-5 signaling. This reduces eosinophil proliferation, differentiation, recruitment, and survival — directly targeting the immunopathologic cascade underlying EGPA.
Dosage Forms & Administration
Vanik is available as a 300 mg/2 mL (150 mg/mL) single-dose prefilled syringe and as a 300 mg lyophilized powder for IV infusion reconstitution. The recommended dose is 300 mg subcutaneously every 4 weeks, administered by a healthcare professional or trained patient in an appropriate clinical setting.
Storage & Handling
Store Vanik refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Once removed from refrigeration, Vanik may be stored at room temperature up to 25°C (77°F) for a maximum of 14 days. Discard if not used within this period. Do not shake the prefilled syringe.
Indication at a Glance
Vanik is indicated for adult patients with moderate-to-severe relapsing EGPA who have demonstrated inadequate response to corticosteroids and/or other immunosuppressive agents. It is not indicated for the treatment of acute bronchospasm or status asthmaticus.
Key Clinical Evidence
  • VANQUISH-1 Trial: 54% of patients achieved sustained remission at Week 52 vs. 19% placebo
  • VANQUISH-2 OLE: Durable response maintained through 3 years in relapsing patients
  • Significant reduction in annualized relapse rate (ARR) of 72% vs. standard of care
  • Oral corticosteroid dose reduced by ≥50% in 68% of patients at Week 36
Safety Information & Patient Support

⚠ BOXED WARNING — Serious Hypersensitivity Reactions: Anaphylaxis and serious allergic reactions have been observed following administration of Vanik. These reactions can occur within hours to days after administration. Discontinue Vanik immediately and initiate appropriate therapy if anaphylaxis or a severe hypersensitivity reaction occurs. Do not readminister Vanik to patients who have experienced a severe hypersensitivity reaction.
Contraindications
  • Known hypersensitivity to vanelizumab-vxk or any excipient in the Vanik formulation
  • Active, uncontrolled helminth (parasitic) infection prior to initiation
  • Concurrent live or live-attenuated vaccine administration
Most Common Adverse Events (≥5%)
  • Injection site reactions (erythema, swelling, pain) — 22%
  • Nasopharyngitis — 18%
  • Headache — 14%
  • Fatigue — 11%
  • Upper respiratory tract infection — 9%
  • Back pain — 7%
Vandoz Patient Connect™ Program
Vandoz Pharma is committed to ensuring patients who may benefit from Vanik can access it. The Vandoz Patient Connect™ program offers comprehensive support:
💳 Co-Pay Card
Eligible commercially insured patients may pay as little as $0/month for Vanik with the Vandoz Co-Pay Assistance Card.
👩‍⚕️ Nurse Navigator
Dedicated nurse navigators available Mon–Fri 8am–8pm ET. Call 1-800-VDZ-CARE for personalized onboarding support.
🏥 Specialty Pharmacy
Vanik is distributed exclusively through certified specialty pharmacy partners. Ask your coordinator for preferred network access.
VandozCare™ — Comprehensive Patient Support Services
VandozCare is Vandoz Pharma's dedicated patient support program designed to help patients navigate every step of their Vanik treatment journey. From insurance verification to ongoing therapy management, VandozCare provides personalized assistance at no cost to patients and their care teams.
Financial Assistance
Co-pay support, patient assistance programs for eligible uninsured/underinsured patients, and free drug program for qualifying individuals
Insurance Navigation
Benefits verification, prior authorization support, appeals assistance, and specialty pharmacy coordination
Treatment Support
Injection training resources, adherence reminders, nurse educator consultations, and side effect management guidance
Educational Resources
Disease state education materials, treatment expectation guides, lifestyle and wellness tips, and caregiver support materials
How to Enroll in VandozCare
  1. Your healthcare provider submits a Vanik prescription
  1. VandozCare team contacts you within 48 hours
  1. Complete enrollment and benefits verification
  1. Receive your personalized support plan and welcome kit
Contact VandozCare
VandozCare Patient Services
Phone: 1-800-VDZ-CARE (1-800-839-2273)
Hours: Monday–Friday, 8:00 AM – 8:00 PM ET
Email: support@vandozcare.com
Online Portal: www.vandozcare.com

VandozCare services are provided at no cost to patients. Eligibility for financial assistance programs is based on insurance status and household income. Terms and conditions apply.
HCP Portal & Clinical Resources
The Vandoz Pharma Healthcare Professional Portal provides prescribers, pharmacists, and clinical staff with verified access to full prescribing information, educational resources, sample requests, and peer-reviewed clinical data. Access is restricted to licensed U.S. healthcare professionals.
🔐 HCP Secure Portal Login
Verified HCPs may log in to access:
  • Full Prescribing Information (PI) & REMS documents
  • Speaker bureau and CME event registration
  • Sample request and voucher management
  • Reimbursement & prior authorization support tools
  • Direct medical affairs inquiry submission
Downloadable Clinical Resources
Full Prescribing Information (PI)
Complete clinical prescribing reference including dosing, safety, pharmacokinetics, and clinical trial data. Updated March 2025. [PDF Placeholder]
FDA-Approved Medication Guide
Patient-facing guide required to be dispensed with every Vanik prescription per FDA MedGuide regulations. [PDF Placeholder]
Patient Education Brochure
Plain-language overview of Vanik's indication, how it works, what to expect during treatment, and support resources available. [PDF Placeholder]
Regulatory Disclaimer: Vanik™ (vanelizumab-vxk) is a fictional investigational product created for demonstration purposes only. This page is not intended as medical advice. All clinical decisions should be made in consultation with a licensed healthcare provider. © 2025 Vandoz Pharma, Inc. All rights reserved. Vandoz Pharma™ and Vandoz Patient Connect™ are trademarks of Vandoz Pharma, Inc. | This material is intended for U.S. healthcare professionals and patients only. PP-VNK-US-0042